Search clinical trials for: Masitinib

Total 650 results

AB Science

Completed

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Mastocytosis
AB Science

Completed

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
AB Science

Completed

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Multiple Myeloma

France
AB Science

Completed

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AB Science

Terminated

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Gastro-Intestinal Stromal Tumour
AB Science

Completed

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Mastocytosis
AB Science

Recruiting

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection

France, Russian Federation, South Africa
AB Science

Completed

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Gastro-intestinal Stromal Tumours

France
AB Science

Completed

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease
AB Science

Completed

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse Free

Poland, Spain, Bulgaria, France, Germany, Greece, Romania
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
AB Science

Completed

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis
AB Science

Completed

Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma

Asthma
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Terminated

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

China
AB Science

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
Beijing Konruns Pharmaceutical Co., Ltd.
West China Hospital; Beijing Tongren Hospital; National Cancer Center/Cancer...

Recruiting

A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Peking University Cancer Hospital & Institute

Completed

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

Breast Neoplasms

China
Bristol-Myers Squibb

Completed

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Pharmacokinetic Study in Healthy Participants

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Beijing Konruns Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Kanitinib in Treating Patients With Advanced Solid Tumors

Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） (FACT)

Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, China

Suspended

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
AB Science

Completed

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Asthma

Malaysia, Argentina, Peru, Philippines, Ukraine
AB Science

Terminated

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France, Singapore, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

Solid Tumor

China
AB Science

Completed

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Asthma

Spain, Bulgaria, Czechia, France, Hungary, India
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
AB Science

Recruiting

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Mast Cell Activation Syndrome

France, United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese...

Completed

A Phase I Study of Famitinib Malate in Patients With Solid Tumor

Advanced Solid Tumor

China
Jiangsu Province Nanjing Brain Hospital

Recruiting

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
AB Science

Recruiting

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

Progressive Multiple Sclerosis

Spain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Solid Tumor

China
Hyoung Jin Kang

Not yet recruiting

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea (VHR ALL)

Acute Lymphoblastic Leukemia, Pediatric
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
AB Science

Terminated

Masitinib in Refractory Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

Czechia
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Xspray Pharma AB
QPS Bioserve India Pvt Limited

Completed

Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

Biological Availability

India

Search clinical trials for: Masitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations